首页 / 产品中心 / 单克隆抗体 /

货号: YP-mAb-06433
促销价:

产品介绍

反应种属
Human;Mouse;Rat
应用范围
WB
抗体类型
单克隆抗体
基因名称(Gene Name)
CCNL2 SB138
蛋白名称
Cyclin-L2 (Paneth cell-enhanced expression protein)
分子量(DA)
57kD
免疫原
Synthesized peptide derived from human protein . at AA range: 400-480
特异性
CCNL2 Monoclonal Antibody detects endogenous levels of protein.
组成
Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
来源
Monoclonal, Mouse,IgG
稀释比例
WB 1:500-2000
纯化工艺
The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.
浓度
1 mg/ml
储存
-20°C/1 year
其他名称
背景
The protein encoded by this gene belongs to the cyclin family. Through its interaction with several proteins, such as RNA polymerase II, splicing factors, and cyclin-dependent kinases, this protein functions as a regulator of the pre-mRNA splicing process, as well as in inducing apoptosis by modulating the expression of apoptotic and antiapoptotic proteins. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2011],
功能
caution:It is uncertain whether Met-1 or Met-6 is the initiator.,domain:Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions.,function:Receptor for a C-C type chemokine. Binds to MIP-3-alpha/LARC and subsequently transduces a signal by increasing the intracellular calcium ions level.,function:Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Also modulates the expression of critical apoptotic factor, leading to cell apoptosis.,induction:By interleukin-2.,online information:CC chemokine receptors entry,similarity:Belongs to the cyclin family. Cyclin L subfamily.,similarity:Belongs to the G-protein coupled receptor 1 family.,subunit:Interacts with CDC2L1 or CDC2L2, SFRS2, SFRS7 and POLR2A, the h

展开

产品详情

客户数据及评论 (0)

折叠内容

文献引用

折叠内容

实验方案

折叠内容
>